Christmas 2008: Seasonal Fayre: the impact of appointments timed in proximity to annual milestones on compliance with screening: randomised controlled trial

BMJ

Volumn 337, Issue 7684, 2008, Pages

  Hoff, GeI'R ^a,b,c,d   Bretthauer, Michael ^b,e,f  

^a Department of Hospital Research ^*  (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c Telemark Hospital   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f New England Journal of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HOSPITAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URBAN POPULATION; COLORECTAL TUMOR; EPIDEMIOLOGY; HEALTH; HISTORY; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; OCCULT BLOOD; PATIENT ATTITUDE; SIGMOIDOSCOPY; STATISTICS;

ANNIVERSARIES AND SPECIAL EVENTS; APPOINTMENTS AND SCHEDULES; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; RURAL HEALTH; SIGMOIDOSCOPY; URBAN HEALTH;

EID: 61449158036     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a2794     Document Type: Article

References (18)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
2. Petersen G. Barriers to preventive intervention. Gastroenterol Clin N Am 2002;31:1061-8.
3. Dulai GS, Farmer MM, Ganz PA, Berbaards CA, Qi K, Doetrich AJ, et al. Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer 2004;100:1843-52.
4. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark polyp study 1983-1996. Eur J Cancer Prev 2001;10:131-7.
5. Department of Health and Ageing, Australian Government. National Bowel Cancer Screening Program. www.cervicalscreen.health.gov.au/internet/screening/ publishing.nsf/Content/bowel-about. 2008.
6. Gondal G, Grotmol G, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implications for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-42.
7. Bretthauer M, Gondal G, Larsen IK, Carlsen E, Eide TJ, Grotmol T, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia. Scand J Gastroenterol 2002;37:568-73.
8. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline findings of the Italian multicenter randomised controlled trial of "once-only sigmoidoscopy" - SCORE. J Natl Cancer Inst 2002;94:1763-72.
9. UK Flexible Sigmoidscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomized trial. Lancet 2002;359:1291-300.
10. Blom J, Liden A, Jeppson B, Holmberg L, Påhlman L. Compliance and findings in a Swedish population screened for colorectal cancer with sigmoidoscopy. Eur J Surg Oncol 2002;28:827-31.
11. Rasmussen M, Kronborg O, Fenger C, Jørgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999;34:73-8.
12. Cole SR, Smith A, Wilson C, Turnbull D, Esterman A, Young GP. An advancenotification letter increasesparticipation in colorectal cancer screening. J Med Screen 2007;14:73-5.
13. Hoff G. Colorectal cancer screening: review of the evidence and suggestions on when and how tomove on from randomized trials to screening programmes. Scand J Gastroenterol 2004;39:99-103.
14. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126:1674-80.
15. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
16. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
17. Dybdahl JH, Haug K, Bakkevold K, Olsen KO, Vetvik K. Screening for occult faecal blood loss in a community by means of Hemoccult-II slides and a tetramethylbenzindine test. Scand J Gastroenterol 1984;19:343-9.
18. Wardle J, Miles A, Atkin W. Gender differences in utilization of colorectal cancer screening. J Med Screen 2005;12:20-7.